Skip to main content

Klee Justin B.'s Form 4 filing

Amylyx Pharmaceuticals, Inc.AMLX · filed Nov 12, 2026

Accession no.
0001193125-26-458246
Filed
Nov 12, 2026, 4:00 PM ET
Trade date
Nov 9, 2026
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $2.98M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Klee Justin B.CIK 0001898314Director, Officer (Co-Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 9, 2026Common StockSSaleDisposed−37,483$29.39F2−$1,101,689.093,575,573Direct
Nov 9, 2026Common StockSSaleDisposed−62,517$30.11F3−$1,882,149.313,513,056Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.72 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)